Healthcare Industry News: Acute Coronary Syndrome
News Release - February 2, 2007
GlaxoSmithKline Receives Approvable Letter for New Indications for ARIXTRA(R) (Fondaparinux Sodium) InjectionPHILADELPHIA, Feb. 2 (HSMN NewsFeed) -- GlaxoSmithKline (GSK) announced today that the U.S. Food and Drug Administration (FDA) has issued an approvable letter for the once-daily anticoagulant, ARIXTRA (fondaparinux sodium) Injection, for the treatment of patients with
- Unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI)
- ST-segment elevation myocardial infarction (STEMI).
- UA/NSTEMI and STEMI are types of Acute Coronary Syndromes (ACS).
GlaxoSmithKline is one of the world's leading research-based pharmaceutical and healthcare companies. GlaxoSmithKline is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information visit http://www.gsk.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.